Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 205

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 12
Chunk 205
---
 Utilities(4,093)(745)Capital Expenditures(1,254)(141)Other Segment Adjusted EBITDA(49,465)(2,361)Segment Adjusted EBITDA$(77,542)$4,997 $(72,545)Other Segment EBITDA for each reportable segment in the table above includes:–Biopharmaceuticals – external R&D costs including laboratory supplies, third-party commercialization and manufacturing costs, consultant costs, legal and professional fees, insurance, and certain other overhead expenses and EBITDA adjustments. –Exemplar – cost of sales, external R&D costs including laboratory supplies, sales and marketing expenses, third-party consultants, supplies, insurance, and certain overhead expenses and EBITDA adjustments. Total segment revenues from reportable segments equal total consolidated revenues.

F-43

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:Year Ended December 31,202420232022Segment Adjusted EBITDA for reportable segments$(83,216)$(76,065)$(72,545)Remove cash paid for capital expenditures net of proceeds from sale of assets8,524 1,438 1,395 Interest Income1,418 3,237 133 Add recognition of previously deferred revenue associated with upfront and milestone payments— — 14,561 Other expenses:Interest expense(6)(468)(6,774)Depreciation and amortization(4,526)(6,668)(7,191)Gain (loss) from disposals of assets2 72 — Impairment losses(40,324)(10,835)(1,120)Stock-based compensation expense(9,471)(9,888)(10,197)Adjustment related to accrued bonuses paid in equity awards3,039 3,361 1,698 Equity in net income (loss) of affiliates— — 862 Shares issued for payment of services(553)(545)(575)Other— (1)(107)Reversal of cumulative foreign translation losses(2,915)— — Eliminations— — (106)Consolidated loss from continuing operations before income taxes$(128,028)$(96,362)$(79,966)For the years ended December 31, 2024, 2023, and 2022, 58.1%, 74.6%, and